2. Antibody-drug Conjugate/ADC Related Anti-infection
  3. ADC Payload Bacterial Antibiotic
  4. Sandramycin

Sandramycin 是一种从 Nocardioides sp 的培养液中分离出来的一种环状十肽抗菌素。Sandramycin 也可以有效地结合 DNA，并且是一种 ADC 的毒素分子。Sandramycin 对革兰氏阳性细菌 (Gram-positive bacteria) 具有活性，并具有有效的抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sandramycin

Sandramycin Chemical Structure

CAS No. : 100940-65-6

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg 询价 3 - 4 周
5 mg 询价

* Please select Quantity before adding items.

Customer Review

Sandramycin 相关抗体

Top Publications Citing Use of Products

查看 ADC Payload 亚型特异性产品:

查看所有亚型
Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

查看 Antibiotic 亚型特异性产品:

查看所有亚型
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity[1][2][3].

IC50 & Target[1]

Traditional Cytotoxic Agents

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
786-0 IC50
8 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
10.1016/S0960-894X(97)00129-7
B16 IC50
0.4 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)
10.1016/S0960-894X(97)00129-7
BT-549 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)
10.1016/S0960-894X(97)00129-7
EBC-1 IC50
1.4 nM
Compound: Sandramycin
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
H322 IC50
20 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)
10.1016/S0960-894X(97)00129-7
HL-60 IC50
80 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)
10.1016/S0960-894X(97)00129-7
HT-29 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)
10.1016/S0960-894X(97)00129-7
IGROV-1 IC50
1.6 nM
Compound: Sandramycin
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
L1210 IC50
0.02 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)
10.1016/S0960-894X(97)00129-7
MCF7 IC50
300 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)
10.1016/S0960-894X(97)00129-7
MOLT-4 IC50
0.7 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)
10.1016/S0960-894X(97)00129-7
OVCAR-3 IC50
1 nM
Compound: Sandramycin
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay
[PMID: 37307297]
OVCAR-3 IC50
4 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)
10.1016/S0960-894X(97)00129-7
PC-3 IC50
0.2 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)
10.1016/S0960-894X(97)00129-7
SK-MEL-28 IC50
1 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)
10.1016/S0960-894X(97)00129-7
SiHa IC50
0.3 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)
10.1016/S0960-894X(97)00129-7
UCLA P-3 IC50
10 nM
Compound: 1 (Sandramycin)
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)
10.1016/S0960-894X(97)00129-7
体外研究
(In Vitro)

Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec+) A22508-2, B. subtilis (Rec-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC50 values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sandramycin 相关抗体:
体内研究
(In Vivo)

Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CDF1 female mice injected with leukemia P388 cells[1]
Dosage: 0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg
Administration: Intraperitoneal injection; daily; for 5 days
Result: Was moderately active in vivo against leukemia P388 in mice.
分子量

1221.32

Formula

C60H76N12O16
CAS 号
中文名称

山卓霉素
结构分类
初始来源

Nocardioides sp.
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Sandramycin 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sandramycin100940-65-6山卓霉素ADC PayloadBacterialAntibioticADC CytotoxinDNAintercalatordepsipeptideantibioticantitumorGram-positivebis-intercalationCytotoxinADCInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Sandramycin
目录号：
HY-19829
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z